EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Our Journey from Individual Efforts to Nationwide Support: Implementing Newborn Screening for Spinal Muscular Atrophy in Serbia

Miloš Brkušanin iD, Nemanja Garai iD, Jelena Karanović iD, Tamara Šljivančanin Jakovljević iD, Aleksandra Dimitrijević, Kristina Jovanović iD, Tanja Lazić Mitrović, Željko Miković, Goran Brajušković iD, Dimitrije Mihailo Nikolić iD, Dušanka Savić-Pavićević iD

International Journal of Neonatal Screening · 15.08.2024 · 10 (3) · 57

DOI: 10.3390/ijns10030057 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Neonatal Screening, online erschienen am 15.08.2024. Verfasst von Miloš Brkušanin und 10 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Human Molecular Genetics, Faculty of Biology, University of Belgrade, 11000 Belgrade, Serbia. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Novartis Gene Therapies Switzerland GmbH, Novartis Gene Therapies (Basel, Switzerland), Roche d.o.o. (Belgrade, Serbia).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Innovative treatments for spinal muscular atrophy (SMA) yield the utmost advantages only within the presymptomatic phase, underlining the significance of newborn screening (NBS). We aimed to establish statewide NBS for SMA in Serbia. Our stepwise implementation process involved technical validation of a screening assay, collaboration with patient organizations and medical professionals, a feasibility study, and negotiation with public health representatives. Over 12,000 newborns were tested during the 17-month feasibility study, revealing two unrelated SMA infants and one older sibling. All three children received therapeutic interventions during the presymptomatic phase and have shown no signs of SMA. No false-negative results were found among the negative test results. As frontrunners in this field in Serbia, we established screening and diagnostic algorithms and follow-up protocols and raised awareness among stakeholders about the importance of early disease detection, leading to the incorporation of NBS for SMA into the national program on 15 September 2023. Since then, 54,393 newborns have been tested, identifying six SMA cases and enabling timely treatment. Our study demonstrates that effective collaborations between academia, non-profit organizations, and industry are crucial in bringing innovative healthcare initiatives to fruition, and highlights the potential of NBS to revolutionize healthcare outcomes for presymptomatic SMA infants and their families.

Schlagwörter

Stichwörter der Autor:innen

SMN1feasibility studygenetic testingmotor neuron diseaseneonatal screeningnewborn screeningpopulation screeningpublic healthreal-time PCRspinal muscular atrophy

Autor:innen und Institutionen

  • Centre for Human Molecular Genetics, Faculty of Biology, University of Belgrade, 11000 Belgrade, Serbia.
  • Department of Neonatology, Obstetrics and Gynaecology Clinic Narodni Front, 11000 Belgrade, Serbia.
  • Department of Gynecology and Obstetrics, Faculty of Medical Sciences, University of Kragujevac, 34000 Kragujevac, Serbia.
  • Gynaecology and Obstetrics Clinic, Clinical Centre of Kragujevac, 34000 Kragujevac, Serbia.
  • Neurology Department, University Children's Hospital, 11000 Belgrade, Serbia.
  • High-Risk Pregnancy Unit, Obstetrics and Gynaecology Clinic Narodni Front, 11000 Belgrade, Serbia.

ORCID-Profile: Miloš Brkušanin, Nemanja Garai, Jelena Karanović, Tamara Šljivančanin Jakovljević, Kristina Jovanović, Goran Brajušković, Dimitrije Mihailo Nikolić, Dušanka Savić-Pavićević

Förderung

  • Novartis Gene Therapies Switzerland GmbH
  • Novartis Gene Therapies (Basel, Switzerland)
  • Roche d.o.o. (Belgrade, Serbia)
  • Medis Pharma d.o.o. (Belgrade, Serbia)

Zitieren

APA

Brkušanin, M., Garai, N., Karanović, J., Šljivančanin Jakovljević, T., Dimitrijević, A., Jovanović, K., Mitrović, T. L., Miković, Ž., Brajušković, G., Nikolić, D. M., & Savić-Pavićević, D. (2024). Our Journey from Individual Efforts to Nationwide Support: Implementing Newborn Screening for Spinal Muscular Atrophy in Serbia. International Journal of Neonatal Screening, 10(3), 57. https://doi.org/10.3390/ijns10030057

Vancouver

Brkušanin M, Garai N, Karanović J, Šljivančanin Jakovljević T, Dimitrijević A, Jovanović K, et al. Our Journey from Individual Efforts to Nationwide Support: Implementing Newborn Screening for Spinal Muscular Atrophy in Serbia. International Journal of Neonatal Screening. 2024;10(3):57. doi:10.3390/ijns10030057

BibTeX
@article{Brkuanin2024,
  author = {Brkušanin, Miloš and Garai, Nemanja and Karanović, Jelena and Šljivančanin Jakovljević, Tamara and Dimitrijević, Aleksandra and Jovanović, Kristina and Mitrović, Tanja Lazić and Miković, Željko and Brajušković, Goran and Nikolić, Dimitrije Mihailo and Savić-Pavićević, Dušanka},
  title = {Our Journey from Individual Efforts to Nationwide Support: Implementing Newborn Screening for Spinal Muscular Atrophy in Serbia},
  journal = {International Journal of Neonatal Screening},
  year = {2024},
  volume = {10},
  number = {3},
  pages = {57},
  doi = {10.3390/ijns10030057}
}
Kostenlos starten →